This prospective, randomized controlled trial assessed the therapeutic effects of major ozone autohemotherapy (O 3-MAH) in patients with post-acute sequelae of COVID-19 (PASC). Seventy-three eligible participants were randomly assigned to an O 3-MAH plus conventional therapy group (n=35) or an conventional therapy alone group (n=38). Symptom score, pulmonary function, 6-minute walk distance (6MWD), and hematological, biochemical, and immunological parameters were evaluated before and after the interventions. Both groups demonstrated improvements in various parameters post-intervention, but efficacy was greater in the O 3-MAH group than the conventional treatment group; with intervention effectiveness defined as a ≥50% reduction in symptom score, 25 of 35 patients (71%) responded to O 3-MAH, while 17/38 patients (45%) responded to conventional treatment alone (P=0.0325). Significant improvements in symptom scores (P=0.0478), tidal volume (P=0.0374), predicted 6MWD (P=0.0032), and coagulation and inflammatory indicators were noted in the O 3-MAH group compared with the conventional treatment group. O­ 3-MAH was more likely to be effective in patients with elevated CRP levels. Furthermore, O 3-MAH markedly improved cellular immunity, and this improvement became more pronounced with extended treatment duration. In summary, combining O 3-MAH with conventional treatment was more effective than conventional therapy alone in improving symptoms, pulmonary function, inflammation, coagulation, and cellular immunity in patients with PASC. Further research is now warranted to validate these findings and establish the longer-term benefits of O 3-MAH for PASC.

Abstract: The aim of this study is to evaluate the clinical characteristics and outcomes in 2019 novel coronavirus patients and to help clinicians perform correct treatment and evaluate prognosis and guide the treatment. Methods: 239 patients who were diagnosed with COVID-19 were included in this study. Patients were divided into the improvement group and the death group according to their outcome (improvement or death).Clinical characteristics and laboratory parameters were collected from medical records. Continuous variables were tested by independent sample T test, and categorical variables were analyzed by chi-square test or Fisher exact test. Cox proportional hazard regression model was used for survival analysis in death patients. Results: Efficacy evaluation indicated that 99 patients (41.4%) had deteriorated, and 140 patients (58.6%) had improved. Oxygen saturation, hemoglobin levels, infection-related indicators, lymphocyte and platelets counts, C-reactive protein, serum albumin, liver and kidney function and lactate dehydrogenase in improvement group were statistically significant between the improvement and death groups. Survival analysis revealed that upper respiratory tract symptoms, hypertension, pulmonary basic diseases, high level of white blood cells, lymphocyte counts, C-reactive protein, lower serum albumin, blood urea nitrogen, were associated with mortality risk in COVID-19. Conclusion: Patients with older age, comorbidities, lower lymphocyte counts in hemogram and serum albumin, high c reactive protein level and renal dysfunction may have higher risk to death. It warned us that more attention should be given more attention on risk management in the progression of COVID-19.